



Published in final edited form as:

Cell Rep. 2018 June 26; 23(13): 3750–3758. doi:10.1016/j.celrep.2018.05.099.

Anti-microbial Functions of Group 3 Innate Lymphoid Cells in Gut-Associated Lymphoid Tissues Are Regulated by G-Protein-Coupled Receptor 183

Coco Chu^{#1}, Saya Moriyama^{#1}, Zhi Li², Lei Zhou^{1,3}, Anne-Laure Flamar¹, Christoph S.N. Klose¹, Jesper B. Moeller^{1,4}, Gregory G. Putzel¹, David R. Withers², Gregory F. Sonnenberg^{1,3}, and David Artis^{1,6,*}

¹Jill Roberts Institute for Research in Inflammatory Bowel Disease, Joan and Sanford I. Weill Department of Medicine, Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA

²Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK

³Gastroenterology and Hepatology Division, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY 10021, USA

⁴Department of Molecular Medicine, University of Southern Denmark, Odense 5000, Denmark

⁶Lead Contact

These authors contributed equally to this work.

SUMMARY

The intestinal tract is constantly exposed to various stimuli. Group 3 innate lymphoid cells (ILC3s) reside in lymphoid organs and in the intestinal tract and are required for immunity to enteric bacterial infection. However, the mechanisms that regulate the ILC3s *in vivo* remain incompletely defined. Here, we show that GPR183, a chemotactic receptor expressed on murine and human ILC3s, regulates ILC3 migration toward its ligand 7 α ,25-dihydroxycholesterol (7 α ,25-OHC) *in vitro*, and GPR183 deficiency *in vivo* leads to a disorganized distribution of ILC3s in mesenteric lymph nodes and decreased ILC3 accumulation in the intestine. GPR183 functions intrinsically in ILC3s, and GPR183-deficient mice are more susceptible to enteric bacterial infection. Together, these results reveal a role for the GPR183-7 α ,25-OHC pathway in regulating the accumulation,

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

*Correspondence: dartis@med.cornell.edu.

AUTHOR CONTRIBUTIONS

C.C. and S.M. carried out most experiments and analyzed the data with help from Z.L., L.Z., A.-L.F., C.S.N.K., J.B.M., D.R.W., and G.F.S. G.G.P. performed RNA-seq analysis. C.C., S.M., and D.A. conceived the project and wrote the manuscript with input from all co-authors.

DECLARATION OF INTERESTS

The authors declare no competing interests.

SUPPLEMENTAL INFORMATION


Supplemental Information includes Supplemental Experimental Procedures and four figures and can be found with this article online at <https://doi.org/10.1016/j.celrep.2018.05.099>.

distribution, and anti-microbial and tissue-protective functions of ILC3s and define a critical role for this pathway in promoting innate immunity to enteric bacterial infection.

In Brief

Chu et al. demonstrate that GPR183 and its ligand 7 α ,25-OHC regulate the accumulation, distribution, and antimicrobial and tissue-protective functions of group 3 innate lymphoid cells, thus revealing a critical role for this pathway in promoting innate immunity against enteric bacterial infection.

Graphical Abstract



INTRODUCTION

The intestinal mucosal barrier surface is constantly exposed to food antigens, beneficial microbes, pathogens, and a multitude of other environmental stimuli (Turner, 2009). Innate lymphoid cells (ILCs) are known to contribute to innate and adaptive immune responses against these stimuli and play a critical role in maintaining barrier function and intestinal homeostasis (Artis and Spits, 2015; Diefenbach et al., 2014; Eberl et al., 2015; Klose and Artis, 2016; Spits et al., 2013, 2016). ILCs are lineage-negative (Lin⁻), interleukin-7 (IL-7) receptor α -positive (CD127⁺), CD90⁺ innate immune cells that are widely distributed throughout the body, particularly enriched at the mucosal barriers (Artis and Spits, 2015; Diefenbach et al., 2014; Eberl et al., 2015; Klose and Artis, 2016). Group 3 ILCs (ILC3s) express the transcription factor ROR γ t and play pivotal roles in protecting against bacterial, viral, and fungal infections in the intestine by fortifying the epithelial barrier via rapid secretion of soluble factors, such as IL-22, lymphotoxin α , and IL-17A, as well as regulating CD4⁺ T cell responses toward intestinal commensal bacteria (Fernandes et al., 2014; Gladiator et al., 2013; Hepworth et al., 2013, 2015; Kim et al., 2012; Klose et al., 2013; Satoh-Takayama et al., 2008). ILC3s are enriched in lymphoid tissues and at mucosal barrier

surfaces, such as the intestinal tract, protecting against hazardous environmental stimuli together with other immune cells (Artis and Spits, 2015; Diefenbach et al., 2014; Eberl et al., 2015; Klose and Artis, 2016). Immune cells express various G-protein-coupled receptors (GPRs), including C-C motif chemokine receptors (CCRs), C-X-C motif chemokine receptors, and other GPRs, such as GPR183 and sphingosine-1-phosphate receptors, which regulate cell migration, accumulation, and distribution in tissues. Several chemokine receptors have been reported to control the accumulation of a subset of the ILC3s (Ivanov et al., 2006; Kim et al., 2015; Mackley et al., 2015; Satoh-Takayama et al., 2014); however, the molecular mechanisms that regulate the accumulation, distribution, and function of the entire ILC3 population in lymphoid and mucosal tissues and their effects on anti-bacterial responses and tissue protection are incompletely defined.

GPR183 (also known as EBI2) is a G α -coupled seven-transmembrane chemotactic receptor. It is highly expressed on follicular B cells, CD4⁺ dendritic cells (DCs), and CD4⁺ T cells but is downregulated on germinal center (GC) B cells in secondary lymphoid organs and controls cell migration to achieve efficient antibody responses and CD4⁺ T cell responses (Gatto et al., 2009, 2013; Li et al., 2016; Pereira et al., 2009; Yi and Cyster, 2013; Yi et al., 2012). GPR183 ligand, 7 α ,25-dihydroxycholesterol (7 α ,25-OHC), is produced by stromal cells residing in the interfollicular regions of lymph nodes (LNs) and the bridging channels of the spleen (Hanne-douche et al., 2011; Liu et al., 2011; Yi et al., 2012). GPR183 expressed on CD4⁺ ILC3s (also termed as lymphoid tissue inducer cells [LTis]) controls their migration and the formation of colonic tertiary lymphoid organs (Emgård et al., 2018). However, whether GPR183 and 7 α ,25-OHC control the accumulation, distribution, and tissue-protective function of ILC3s in the gut-associated lymphoid tissues and in the intestinal lamina propria (LP) has not been examined.

In this study, we demonstrate that ILC3s isolated from the mesenteric LNs (mLNs) and intestinal LP express GPR183 and intestinal ILC3s migrate toward 7 α ,25-OHC *in vitro*. Quantitative PCR (qPCR) analysis indicated 7 α ,25-OHC production by gut stromal cells, and genetic deletion of GPR183 or 7 α ,25-OHC resulted in a disorganized accumulation of ILC3s in the subcapsular sinus of the mLNs and reduced ILC3 accumulation in the intestine. The regulation of ILC3 accumulation in the intestine by GPR183 was ILC3 intrinsic and was required for optimal IL-22 production and protective immunity against the enteric bacterium, *Citrobacter rodentium* (*C. rodentium*). Taken together, these data reveal a previously unrecognized role of the GPR183-7 α ,25-OHC pathway in regulating ILC3-dependent immunity to enteric bacterial infection.

RESULTS

GPR183 Is Constitutively Expressed on ILC3s and Mediates Migration toward 7 α ,25-OHC

To study the pathways that regulate the distribution and accumulation of ILC3s in lymphoid and mucosal tissues *in vivo*, we undertook an unbiased analysis of molecules associated with these processes by RNA sequencing (RNA-seq). Among the genes listed in the gene ontology (GO) term “lymphocyte chemo-taxis,” *Gpr183* was the most abundant gene expressed in intestinal LP ILC3s (Figure S1A). To further examine this, we sorted ILC subsets from intestinal LP cells as well as mLN cells harvested from *Rorc*(γ t)^{Gfp} mice and

analyzed the expression of *Gpr183* mRNA by quantitative PCR. Consistent with the RNA-seq data, intestinal CCR6⁺ ILC3s and CCR6⁻ ILC3s and mLN ILC3s had high *Gpr183* mRNA expression, and the expression in intestinal CCR6⁺ ILC3s was higher than in ILC1s and ILC2s (Figure 1A). To examine GPR183 protein expression, we employed *Gpr183^{LacZ/+}* reporter mice, which were generated by replacing the *Gpr183* coding region with the *LacZ* gene, and we could detect LacZ expression in non-GC B cells, but not in GC B cells (Figure S1B). We confirmed the LacZ expression in mLN and small intestinal (SI) ILC3s (Figure 1B; gating strategy in Figure S1C). We also detected GPR183 protein staining on CD45⁺Lin⁻CD127⁺CD117⁺CRTH2⁻ cells, which are ILC3s in human ileal LP and ILC precursors in peripheral blood mononuclear cells (PBMCs) (Lim et al., 2017) from healthy donors (Figures 1C and 1D; gating strategy in Figure S1D). Collectively, these data show that murine and human ILC3s express GPR183.

Given that GPR183 is a chemotactic receptor expressed on follicular B cells, CD4⁺ T cells, and DCs, mediating their migration toward the GPR183 ligand 7 α ,25-OHC (Gatto et al., 2009, 2013; Li et al., 2016; Pereira et al., 2009; Yi and Cyster, 2013; Yi et al., 2012), we tested whether ILC3s migrate toward 7 α ,25-OHC *in vitro*. We performed transwell migration assays with SILP cells from wild-type (WT) mice and *Gpr183^{-/-}* mice. WT ILC3s migrated toward 7 α ,25-OHC *in vitro*, whereas *Gpr183^{-/-}* ILC3s did not, indicating that GPR183 regulates ILC3s migration toward 7 α ,25-OHC (Figure 1E).

CH25H and CYP7B1 Are Expressed in Intestinal Stromal Cells

Cholesterol 25-hydroxylase (CH25H) and oxysterol 7 α -hydroxy-lase (CYP7B1), which are enzymes required for the biosynthesis of GPR183 ligand 7 α ,25-OHC, are highly expressed in spleen and LN stromal cells (Hannedouche et al., 2011; Liu et al., 2011; Yi et al., 2012). To determine whether CH25H and CYP7B1 are also expressed in intestinal stromal cells, we fractionated mouse SI into epithelial, LP leukocyte (LPL), and stromal compartments and measured the relative expression of *Ch25h* and *Cyp7b1* mRNA in each compartment by qPCR. Expression of *Ch25h* and *Cyp7b1* was higher in the stromal compartment compared to epithelial and LPL compartments of the SI (Figure 1F), suggesting 7 α ,25-OHC production by intestinal stromal cells. Together with previous reports (Emgård et al., 2018; Yi et al., 2012), these data indicate that the interaction of GPR183 expressed on ILC3s and 7 α ,25-OHC produced by stromal cells in mLNs and the intestine may control the accumulation of ILC3s in these organs.

GPR183 and 7 α ,25-OHC Control the Distribution of ILC3s in mLNs

To examine the effect of GPR183 deficiency on ILC3s at steady state *in vivo*, we analyzed ILC3s from WT mice and *Gpr183^{-/-}* mice using flow cytometry. Percentages of ROR γ t⁺ ILC3s within the total ILC population (CD45⁺Lin⁻CD90⁺CD127⁺; refer to the gating strategy in Figure S2A) were significantly increased in the mLNs of *Gpr183^{-/-}* mice, along with increased ILC3 numbers compared to WT mice (Figures 2A and 2B). The frequencies and numbers of NKp46⁺ROR γ t⁻ ILC1s and GATA-3⁺ ILC2s were reduced in *Gpr183^{-/-}* mice compared to WT mice (Figures S2B and S2C). *Ch25h^{-/-}* mice that have defective 7 α ,25-OHC production (Hannedouche et al., 2011; Liu et al., 2011) exhibited increased ILC3s,

reduced ILC1s, and comparable ILC2s in the mLNs compared to WT mice at steady state (Figures 2C, 2D, S2D, and S2E).

Previous studies identified that the localization of GPR183-expressing T cells, B cells, and DCs within lymphoid tissues is regulated by $7\alpha,25$ -OHC produced from tissue stromal cells (Gatto et al., 2009, 2013; Hannedouche et al., 2011; Li et al., 2016; Liu et al., 2011; Pereira et al., 2009; Yi and Cyster, 2013; Yi et al., 2012). To examine whether GPR183 regulates the localization of ILC3s in mLNs, we stained mLN sections from WT mice and *Gpr183*^{-/-} mice with anti-ROR γ t, CD3e, and CD127 antibodies to visualize ILC3s (Figure 2E). Serial sections were stained for B220 or MAdCAM-1 to examine the position of follicles and the subcapsular sinuses (Figures 2F and 2G). There was no overt difference in the structure of follicles and T cell areas in mLNs from *Gpr183*^{-/-} mice compared to WT mice, which is consistent with the previous report (Pereira et al., 2009). ROR γ t⁺CD3e⁺CD127⁺ ILC3s were found predominantly in the interfollicular areas of WT mLN sections, which is consistent with published results (Hepworth et al., 2015; Mackley et al., 2015). A significantly higher proportion of the *Gpr183*^{-/-} ILC3s were found in the outer regions of the interfollicular areas rather than their normal localization in mLNs compared to that of the WT ILC3s (Figures 2E-2H; refer to Figure S2F for the definition of inner and outer regions). Similarly, staining of mLN sections from WT mice and *Ch25h*^{-/-} mice showed more ILC3s localized in the outer regions of the interfollicular areas of *Ch25h*^{-/-} mLN sections compared to WT mLN sections (Figures 2I, 2J, and S2F). Consistent with the flow cytometry data (Figures 2A and 2B), more ILC3s were found in the interfollicular areas in the *Gpr183*^{-/-} mLN sections compared to WT (Figure 2K). We also examined the Peyer's patches (PPs) and found increased ILC3s in the *Gpr183*^{-/-} PPs compared to WT (Figure S2G). Immunofluorescent staining of PP sections revealed accumulation of ILC3s in between the follicle and the T cell area in the luminal side of *Gpr183*^{-/-} mice (Figure S2H). Collectively, these results suggest that GPR183 and $7\alpha,25$ -OHC control the distribution and accumulation of ILC3s in the mLNs and PPs. Notably, ILC3s from *Gpr183*^{-/-} mice had comparable expression of CCR7 and CCR9 but significantly lower expression of integrin $\alpha 4\beta 7$, which mediates cell trafficking to the intestine (Kim et al., 2015), compared to ILC3s from WT mice (Figures 2L and S2I).

GPR183 and $7\alpha,25$ -OHC Regulate ILC3 Accumulation in the Intestine

Given that GPR183 appears to regulate migration of intestinal ILC3s (Figure 1E) and expression of gut-tropic integrin expression (Figure 2L), we analyzed the accumulation of ILC3s in the SILP of *Gpr183*^{-/-} mice and WT mice. In contrast to mLNs, ROR γ t⁺ ILC3s, including both the NKp46⁺ and CCR6⁺ ILC3 subsets, were significantly reduced in *Gpr183*^{-/-} SILP compared to WT at steady state (Figures 3A-3D). As intestinal stromal cells are potential producers of $7\alpha,25$ -OHC (Figure 1F; Emgård et al., 2018), we also examined the SILP of *Ch25h*^{-/-} mice and found fewer ILC3s in *Ch25h*^{-/-} mice compared to WT mice (Figures 3E-3H). To examine whether GPR183 regulates the localization of ILC3s in the SI, we crossed *Gpr183*^{-/-} mice with *Rorc*(γ t)^{Gfp} mice and stained the SI sections with anti-GFP, CD3e, and B220 antibodies (Figure 3I). WT and *Gpr183*^{-/-} GFP⁺CD3e⁻ ILC3s were similarly scattered in the LP, but *Gpr183*^{-/-} mice had fewer cryptopatches (CPs) compared to WT mice, which is consistent with the flow cytometry data (Figures 3A, 3B, and 3J). When we analyzed the colon LP at steady state, the numbers and proportions of ILCs were

comparable between WT and *Gpr183*^{-/-} mice or *Ch25h*^{-/-} mice (Figures S3A-S3D), but *Gpr183*^{-/-} mice had fewer CPs and isolated lymphoid follicles in the colon compared to WT mice (Figures S3E and S3F). Taken together, these results suggest that, through binding to 7 α ,25-OHC produced by intestinal stromal cells, GPR183 promotes the accumulation of ILC3s in the intestine.

ILC3-Intrinsic Expression of GPR183 Controls Their Accumulation in the Intestine and mLNs

To test whether the regulation of ILC3 accumulation in the intestine and mLNs by GPR183 is ILC3-intrinsic, we generated mixed bone marrow (BM) chimera mice by transferring congenically labeled WT or *Gpr183*^{-/-} cells (CD45.2⁺) mixed with WT BM cells (CD45.1⁺CD45.2⁺) into lethally irradiated recipient mice (CD45.1⁺). After 8 weeks of reconstitution, we examined the ratios of WT or *Gpr183*^{-/-} CD45.2⁺ cells to internal control WT CD45.1⁺CD45.2⁺ cells within ILC3 populations. Compared to WT CD45.2⁺ BM mixed with WT CD45.1⁺CD45.2⁺ BM chimera (WT:WT mice), *Gpr183*^{-/-} CD45.2⁺ BM mixed with WT CD45.1⁺CD45.2⁺ BM chimera (*Gpr183*^{-/-}:WT mice) had significantly reduced ratios of CD45.2⁺ ILC3s to CD45.1⁺CD45.2⁺ ILC3s in the SI (Figures 3K and S3G). We also observed smaller ILC3 percentages in *Gpr183*^{-/-} CD45.2⁺ cells compared to that in WT CD45.1⁺CD45.2⁺ cells in total SI ILCs within each *Gpr183*^{-/-}:WT mice (Figure S3H; 8.3 \pm 0.1 versus 13.4 \pm 0.9; mean \pm SEM; $p < 0.01$). Meanwhile, *Gpr183*^{-/-}:WT mice exhibited significantly increased ratios of CD45.2⁺ ILC3s to CD45.1⁺CD45.2⁺ ILC3s in the mLNs compared to WT:WT mice (Figure 3K).

The expression of the proliferation marker Ki67 was comparable in CD45.1⁺CD45.2⁺ ILC3s (WT) and CD45.2⁺ ILC3s (WT or *Gpr183*^{-/-}) in both chimeras (Figure 3L). Therefore, GPR183 appears to regulate the accumulation, but not the proliferation, of ILC3s in the intestine and mLNs in a cell-intrinsic manner. Moreover, *Gpr183*^{-/-}:WT mice exhibited increased ratios of CD45.2⁺ cells in the ILC1 gate and comparable ratios of ILC2s compared to WT:WT mice, suggesting that the reduced ILC1s and ILC2s in *Gpr183*^{-/-} mLNs was secondary to the cell-intrinsic effect on ILC3s (Figure S3I).

GPR183 Is Required for ILC3-Mediated Protective Immunity following Enteric Bacterial Infection

ILC3s are critical in promoting innate immunity to *C. rodentium* infection through producing IL-22, which triggers the secretion of anti-microbial peptides from intestinal epithelial cells (Sato-Takayama et al., 2008; Sawa et al., 2011; Sonnenberg et al., 2011; Zheng et al., 2008). Considering that GPR183 deficiency hampers ILC3 accumulation in the intestine, we sought to test whether GPR183 regulates ILC3-mediated innate immunity against *C. rodentium* infection. Similar to the SI of *Gpr183*^{-/-} mice (Figures 3A-3D), percentages and numbers of ILC3s were significantly reduced in the SI and the colon of *Rag1*^{-/-}*Gpr183*^{-/-} mice compared to *Rag1*^{-/-} mice at steady state (Figures S4A-S4D). Numbers of NKp46⁺ ILC3s and CCR6⁺ ILC3s were both significantly reduced in *Rag1*^{-/-}*Gpr183*^{-/-} mice (Figures S4E and S4F). At 8 days after *C. rodentium* infection, *Rag1*^{-/-}*Gpr183*^{-/-} mice also exhibited significantly reduced frequencies and numbers of ILC3s in the SI and the colon compared to *Rag1*^{-/-} mice (Figures 4A, 4B, S4G, and S4H).

Similar to steady state, numbers of NKp46⁺ ILC3s and CCR6⁺ ILC3s in the SI were both significantly reduced in infected *Rag1*^{-/-}*Gpr183*^{-/-} mice compared to *Rag1*^{-/-} mice (Figures S4I and S4J). The percentages of Ki67⁺ cells in intestinal ILC3s were comparable between *Rag1*^{-/-} mice and *Rag1*^{-/-}*Gpr183*^{-/-} mice, suggesting that the proliferation of ILC3s during infection is not regulated by GPR183 (Figures 4C and S4K). We next examined whether the IL-22-producing capacity of ILC3s was regulated by GPR183 expression. Notably, both *Rag1*^{-/-} and *Rag1*^{-/-}*Gpr183*^{-/-} ILC3s contained similar percentages of IL-22⁺ cells, suggesting that GPR183 deficiency does not affect the capability of IL-22 production in ILC3s (Figures 4D, S4L, and S4M). However, numbers of IL-22-producing ILC3 were significantly reduced in *Rag1*^{-/-}*Gpr183*^{-/-} compared to *Rag1*^{-/-} mice, due to lower total numbers of ILC3 in *Rag1*^{-/-}*Gpr183*^{-/-} mice (Figures 4E and S4N).

In accordance with reduced numbers of IL-22-producing ILC3s, *Rag1*^{-/-}*Gpr183*^{-/-} mice exhibited significantly more severe colonic crypt hyperplasia, colonic shortening, and more severe loss of body weight compared to *Rag1*^{-/-} mice, indicating impaired ILC3-dependent innate immunity and tissue protection in *Rag1*^{-/-}*Gpr183*^{-/-} mice (Figures 4F-4H). Lipocalin 2 (*Lcn2*) mRNA expression was higher in *Rag1*^{-/-}*Gpr183*^{-/-} mice, which is consistent with exacerbated inflammation compared to *Rag1*^{-/-} mice (Figure 4I). Moreover, *Rag1*^{-/-}*Gpr183*^{-/-} mice exhibited a reduced survival rate following infection compared to *Rag1*^{-/-} mice (Figure 4J). Given the importance of IL-22 in tissue protection following bacterial infection (Satoh-Takayama et al., 2008; Sawa et al., 2011; Sonnenberg et al., 2011; Zheng et al., 2008), these results suggest that GPR183 regulates anti-bacterial responses and tissue protection through facilitating the accumulation of IL-22-producing ILC3s in the intestine. Taken together, these data identify a crosstalk between GPR183-expressing ILC3s and intestinal stromal cells that express 7 α ,25-OHC, which is required for optimal ILC3 responses and host protective immunity against enteric bacterial infection.

DISCUSSION

Mucosal barriers are constitutively challenged by various stimuli, and the homeostasis of mucosal barriers both at steady state and upon challenge are maintained by tissue-resident immune cells (Kurashima et al., 2013; Okumura and Takeda, 2016). ILC3s are found in lymphoid tissues and are enriched in the intestine, where they play critical roles in regulating adaptive immune responses against commensal bacteria, as well as in innate immunity against enteric bacterial infections (Hepworth et al., 2013, 2015; Rankin et al., 2016; Satoh-Takayama et al., 2008; Sawa et al., 2011; Song et al., 2015; Sonnenberg et al., 2011). Although the mechanisms ILC3s employ to control infections and promote tissue repair continue to be defined (Satoh-Takayama et al., 2008; Sawa et al., 2011; Sonnenberg et al., 2011), our understanding of how the accumulation, distribution, and tissue-protective function of ILC3s in the intestine and its associated lymphoid organs are controlled remained limited. Emgård et al. (2018) recently reported that CD4⁺ LTi-like ILC3s express GPR183 that controls cell migration and formation of solitary intestinal lymphoid tissues in the colon and enhances IL-22 production by ILC3s in the colon at steady state. In the current study, we demonstrate that GPR183 is expressed on murine and human ILC3s and that GPR183 and its ligand 7 α ,25-OHC regulate the accumulation and distribution of ILC3s in

lymphoid tissues and the intestine, and consequently, GPR183 controls ILC3-dependent innate immunity and tissue protection following enteric bacterial infection. We also identify GPR183-dependent accumulation of IL-22-producing ILC3s in the intestine following *C. rodentium* infection. Of note, enhanced IL-22 production by ILC3s was not detectable, possibly due to heightened inflammation elicited by the bacterial infection.

ILC3s reside in the interfollicular areas of the mLNs, where they present commensal bacterial antigen through major histocompatibility complex class II and prevent CD4⁺ T cell-induced chronic intestinal inflammation toward commensal bacteria (Hepworth et al., 2015). In this study, we show that GPR183 controls the distribution of ILC3s in mLNs. GPR183-deficient ILC3s accumulated in the outer regions of the inter-follicular areas, which are close to the subcapsular sinuses. DCs migrate into the LNs via the lymph through subcapsular sinuses and then move to the paracortex where they interact with helper T cells (Lian and Luster, 2015). This pathway is regulated by CCR7, a molecule that also controls the accumulation of ILC3s to LNs (Lian and Luster, 2015; Mackley et al., 2015). Similarly, ILC3s migrate from other organs, such as the intestine (Mackley et al., 2015), and enter the LNs through subcapsular sinuses. In the context of GPR183 deficiency, ILC3s cannot migrate into the interfollicular areas because they fail to respond to the ligand expressed in the inner regions of the interfollicular areas and hence are sequestered in the subcapsular sinuses. As GPR183 plays such important roles in regulating the distribution and function of ILC3s in both lymphoid and non-lymphoid tissues, GPR183 itself and its oxysterol ligand-producing pathway could be potential therapeutic targets for controlling and regulating ILC3 functions in multiple infectious and inflammatory diseases.

EXPERIMENTAL PROCEDURES

Further details and an outline of resources used in this work can be found in Supplemental Experimental Procedures.

Mice

C57BL/6 (Jax 664), *Gpr183^{LacZ/+}* (Jax 26443), *Ch25h^{-/-}* (Jax 16263), CD45.1 (Jax 2014), and *Rag1^{-/-}* (Jax 2216) mice were purchased from The Jackson Laboratory. *Rorc(γt)^{Gfp}* was provided by Dr. G. Eberl (Institut Pasteur, France). Breeding of *Gpr183^{LacZ/+}* to homozygosity resulted in *Gpr183*-deficient (*Gpr183^{LacZ/LacZ}*) mice referred to as *Gpr183^{-/-}* throughout the manuscript. Sex- and age-matched WT and transgenic mice between 6 and 16 weeks of age were co-housed and used for experiments. All mice were maintained under specific pathogen-free conditions and were used in accordance with the Institutional Animal Care and Use Committee guidelines at Weill Cornell Medical College.

Isolation and Flow Cytometry Staining of Human ILC3s

Intestinal biopsies from the terminal ileum were obtained, processed, and viably cryopreserved as previously described (Hepworth et al., 2013,2015). Following thawing, cells were stained for CD3 (UCHT1), CD19(HIB19),CD11c(S-HCL-3), CD11b (M1/70), CD14 (M5E2) as lineage markers, and CD45 (HI30), CRTH2 (BM16), CD127 (A019D5), CD117 (104D2), GPR183 (SA313E4), or mouse immunoglobulin G2a (IgG2a), κ

(MOPC-173) was used as isotype control. Dead cells were excluded with the Live/Dead Fixable Aqua Dead Cell Stain Kit. ILCs were gated as CD45⁺Lin⁻CD127⁺, and ILC3s were gated as CD45⁺Lin⁻CD127⁺CRTH2⁻CD117⁺. PBMCs were isolated from buffy coats (New York Blood Center) with a Ficoll-Paque PLUS (GE Healthcare) gradient. All samples were cryopreserved and stored in liquid nitrogen. For staining ILC precursors from PBMCs, cells were incubated with FcR Blocking Reagent (Miltenyi Biotec) and subsequently stained for CD3 (UCHT1), CD123 (6H6), CD5 (UCHT2), FcεRI (AER-37), CD11c (S-HCL-3), CD11b (M1/70), CD34 (581), CD14 (HCD14) as lineage markers and CD19 (HIB19), CD45 (HI30), CRTH2 (BM16), CD94 (DX22), CD127 (A019D5), and CD117 (104D2). For surface receptor expression analysis, anti-GPR183 (SA313E4) or mouse IgG2a, κ isotype control (MOPC-173) was used. Dead cells were excluded with the Live/Dead Fixable Aqua Dead Cell Stain Kit. ILC precursors were gated as CD45⁺Lin⁻CD19⁻CD94⁻CD127⁺CRTH2⁻CD117⁺. All antibodies were purchased from eBioscience, BioLegend, or BD Bioscience.

Quantification and Statistical Analysis

Statistical tests were performed with Prism (GraphPad). Unless specifically indicated otherwise, Student's t tests were used to compare endpoint means of different groups. Error bars depict the SEM. For the comparison of Kaplan-Meier survival curves, log rank (mantel-Cox) test was used. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We thank the Artis lab members and the Sonnenberg lab members for discussion and critical reading of the manuscript. We also thank Dr. G. Eberl for *Rorc*(γ)^{Gip} mice and Dr. B. Vallance for *Citrobacter rodentium*. This work was supported by the grants from the Japan Society for the Promotion of Science Overseas Research Fellowships (to S.M.), the German Research Foundation (KL 2963/1-1 to C.S.N.K.), the Novo Nordisk Foundation (14052 to J.B.M.), the Jill Roberts Institute (to G.G.P.), the Wellcome Trust (Senior Research Fellowship 110199/Z/15/Z to D.R.W.), Cure for IBD (to D.A.), the Crohn's and Colitis Foundation of America (to D.A. and G.F.S.), the Searle Scholars Program (to G.F.S.), an American Asthma Foundation Scholar Award (to G.F.S.), the Burroughs Wellcome Fund (to D.A.), and the NIH (DP5OD012116, AI123368, DK110262, and AI095608 to G.F.S.; AI074878, AI083480, AI095466, AI095608, AI102942, AI097333, and AI106697 to D.A.).

REFERENCES

- Artis D, and Spits H (2015). The biology of innate lymphoid cells. *Nature* 517, 293–301. [PubMed: 25592534]
- Diefenbach A, Colonna M, and Koyasu S (2014). Development, differentiation, and diversity of innate lymphoid cells. *Immunity* 41, 354–365. [PubMed: 25238093]
- Eberl G, Colonna M, Di Santo JP, and McKenzie AN (2015). Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. *Science* 348, aaa6566. [PubMed: 25999512]
- Emgård J, Kammoun H, García-Cassani B, Chesné J, Parigi SM, Jacob JM, Cheng HW, Evren E, Das S, Czarnewski P, et al. (2018). Oxysterol Sensing through the Receptor GPR183 Promotes the Lymphoid-Tissue-Inducing Function of Innate Lymphoid Cells and Colonic Inflammation. *Immunity* 48, 120–132.e8. [PubMed: 29343433]
- Fernandes SM, Pires AR, Ferreira C, Foxall RB, Rino J, Santos C, Correia L, Pocas J, Veiga-Fernandes H, and Sousa AE (2014). Enteric mucosa integrity in the presence of apreserved innate

- interleukin 22 compartment in HIV type 1-treated individuals. *J. Infect. Dis* 210, 630–640. [PubMed: 24604817]
- Gatto D, Paus D, Basten A, Mackay CR, and Brink R (2009). Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses. *Immunity* 31, 259–269. [PubMed: 19615922]
- Gatto D, Wood K, Caminschi I, Murphy-Durland D, Schofield P, Christ D, Karupiah G, and Brink R (2013). The chemotactic receptor EBI2 regulates the homeostasis, localization and immunological function of splenic dendritic cells. *Nat. Immunol* 14, 446–453. [PubMed: 23502855]
- Gladiator A, Wangler N, Trautwein-Weidner K, and LeibundGut-Land-mann S (2013). Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. *J. Immunol* 190, 521–525. [PubMed: 23255360]
- Hannedouche S, Zhang J, Yi T, Shen W, Nguyen D, Pereira JP, Guerini D, Baumgarten BU, Roggo S, Wen B, et al. (2011). Oxysterols direct immune cell migration via EBI2. *Nature* 475, 524–527. [PubMed: 21796212]
- Hepworth MR, Monticelli LA, Fung TC, Ziegler CG, Grunberg S, Sinha R, Mantegazza AR, Ma HL, Crawford A, Angelosanto JM, et al. (2013). Innate lymphoid cells regulate CD4+T-cell responses to intestinal commensal bacteria. *Nature* 498, 113–117. [PubMed: 23698371]
- Hepworth MR, Fung TC, Masur SH, Kelsen JR, McConnell FM, Dubrot J, Withers DR, Hugues S, Farrar MA, Reith W, et al. (2015). Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4⁺ T cells. *Science* 348, 1031–1035. [PubMed: 25908663]
- sIvanov II, Diehl GE, and Littman DR (2006). Lymphoid tissue inducer cells in intestinal immunity. *Curr. Top. Microbiol. Immunol* 308, 59–82. [PubMed: 16922086]
- Kim CJ, Nazli A, Rojas OL, Chege D, Alidina Z, Huibner S, Mujib S, Benko E, Kovacs C, Shin LY, et al. (2012). A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis. *Mucosal Immunol.* 5, 670–680. [PubMed: 22854709]
- Kim MH, Taparowsky EJ, and Kim CH (2015). Retinoic Acid Differentially Regulates the Migration of Innate Lymphoid Cell Subsets to the Gut. *Immunity* 43, 107–119. [PubMed: 26141583]
- Klose CS, and Artis D (2016). Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. *Nat. Immunol* 17, 765–774. [PubMed: 27328006]
- Klose CS, Kiss EA, Schwierzeck V, Ebert K, Hoyler T, d’Hargues Y, Göppert N, Croxford AL, Waisman A, Tanriver Y, and Diefenbach A (2013). A T-bet gradient controls the fate and function of CCR6-ROR γ t⁺ innate lymphoid cells. *Nature* 494, 261–265. [PubMed: 23334414]
- Kurashima Y, Goto Y, and Kiyono H (2013). Mucosal innate immune cells regulate both gut homeostasis and intestinal inflammation. *Eur. J. Immunol* 43, 3108–3115. [PubMed: 24414823]
- Li J, Lu E, Yi T, and Cyster JG (2016). EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells. *Nature* 533, 110–114. [PubMed: 27147029]
- Lian J, and Luster AD (2015). Chemokine-guided cell positioning in the lymph node orchestrates the generation of adaptive immune responses. *Curr. Opin. Cell Biol* 36, 1–6. [PubMed: 26067148]
- Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, Serafini N, Puel A, Bustamante J, Surace L, et al. (2017). Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. *Cell* 170, 1086–1100.e10.
- Liu C, Yang XV, Wu J, Kuei C, Mani NS, Zhang L, Yu J, Sutton SW, Qin N, Banie H, et al. (2011). Oxysterols direct B-cell migration through EBI2. *Nature* 475, 519–523. [PubMed: 21796211]
- Mackley EC, Houston S, Marriott CL, Halford EE, Lucas B, Cerovic V, Filbey KJ, Maizels RM, Hepworth MR, Sonnenberg GF, et al. (2015). CCR7-dependent trafficking of ROR γ ⁺ ILCs creates a unique microenvironment within mucosal draining lymph nodes. *Nat. Commun* 6, 5862. [PubMed: 25575242]
- Okumura R, and Takeda K (2016). Maintenance of gut homeostasis by the mucosal immune system. *Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci* 92, 423–435.
- Pereira JP, Kelly LM, Xu Y, and Cyster JG (2009). EBI2 mediates B cell segregation between the outer and centre follicle. *Nature* 460, 1122–1126. [PubMed: 19597478]

- Rankin LC, Girard-Madoux MJ, Seillet C, Mielke LA, Kerdiles Y, Fenis A, Wieduwild E, Putoczki T, Mondot S, Lantz O, et al. (2016). Complementarity and redundancy of IL-22-producing innate lymphoid cells. *Nat. Immunol* 77, 179–186.
- Satoh-Takayama N, Vosschenrich CA, Lesjean-Pottier S, Sawa S, Lochner M, Rattis F, Mention JJ, Thiam K, Cerf-Bensussan N, Mandelboim O, et al. (2008). Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. *Immunity* 29, 958–970. [PubMed: 19084435]
- Satoh-Takayama N, Serafini N, Verrier T, Rekiki A, Renauld JC, Frankel G, and Di Santo JP (2014). The chemokine receptor CXCR6 controls the functional topography of interleukin-22 producing intestinal innate lymphoid cells. *Immunity* 47, 776–788.
- Sawa S, Lochner M, Satoh-Takayama N, Dulauroy S, Berard M, Klein-schek M, Cua D, Di Santo JP, and Eberl G (2011). ROR γ t+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. *Nat. Immunol* 72, 320–326.
- Song C, Lee JS, Gilfillan S, Robinette ML, Newberry RD, Stappenbeck TS, Mack M, Cella M, and Colonna M (2015). Unique and redundant functions of NKp46+ ILC3s in models of intestinal inflammation. *J. Exp. Med* 272, 1869–1882.
- Sonnenberg GF, Monticelli LA, Elloso MM, Fouser LA, and Artis D (2011). CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. *Immunity* 34, 122–134. [PubMed: 21194981]
- Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie AN, Mebius RE, et al. (2013). Innate lymphoid cells—a proposal for uniform nomenclature. *Nat. Rev. Immunol* 73, 145–149.
- Spits H, Bernink JH, and Lanier L (2016). NK cells and type 1 innate lymphoid cells: partners in host defense. *Nat. Immunol* 77, 758–764.
- Turner JR (2009). Intestinal mucosal barrier function in health and disease. *Nat. Rev. Immunol* 9, 799–809. [PubMed: 19855405]
- Yi T, and Cyster JG (2013). EBI2-mediated bridging channel positioning supports splenic dendritic cell homeostasis and particulate antigen capture. *eLife* 2, e00757. [PubMed: 23682316]
- Yi T, Wang X, Kelly LM, An J, Xu Y, Sailer AW, Gustafsson JA, Russell DW, and Cyster JG (2012). Oxysterol gradient generation by lymphoid stromal cells guides activated B cell movement during humoral responses. *Immunity* 37, 535–548. [PubMed: 22999953]
- Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas AR, Modrusan Z, Ghilardi N, de Sauvage FJ, and Ouyang W (2008). Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nat. Med* 74, 282–289.

Highlights

- ILC3s from mouse mesenteric lymph nodes and mouse and human intestine express GPR183
- GPR183 and its ligand 7 α ,25-OHC promote ILC3 migration *in vitro*
- GPR183 and 7 α ,25-OHC regulate the accumulation and function of ILC3s *in vivo*
- GPR183 is required for ILC3-mediated immunity against enteric bacterial infection




Figure 1. GPR183 Is Expressed on ILC3s and Regulates ILC3 Migration

(A) qPCR analysis of *Gpr183* transcript abundance in indicated sort-purified cell populations presented relative to *Hprt1*. Each symbol represents sample from one mouse or pooled from 2 or 3 mice. Fo B, follicular B cells; GC B, germinal center B cells. *p < 0.05 and ****p < 0.0001 by one-way ANOVA with Dunnett’s multiple comparison.

(B) LacZ staining (conversion of the fluorescent LacZ substrate fluorescein di- β -D-galactopyrano-side [FDG]) indicating GPR183 expression on ILC3s from mLNs and SILP. Data are representative of 2 independent experiments.

(C) Flow cytometry histograms of anti-GPR183 staining on ILC3s (red line), total ILCs (blue line), and isotype control staining on total ILCs (shaded gray) from human terminal ileum. Data are representative of 5 donors.

(D) Flow cytometry histograms of anti-GPR183 staining (red line) and isotype control staining (shaded gray) on ILC precursors from human PBMCs. Data are representative of 4 donors.

(E) *In vitro* migration of ILC3s toward 7 α ,25-OHC. Data are representative of 2 independent experiments. **p < 0.01.

(F) qPCR analysis of 7 α ,25-OHC-producing enzymes *Ch25h* and *Cyp7b1* transcript abundances in fractionated SI samples from WT mice, presented relative to *Hprt1*. LPL, lamina propria leukocyte.

Each symbol represents one mouse unless specifically indicated. Data are mean \pm SEM. See also Figure S1.




Figure 2. Disorganized ILC3 Distribution in the mLNs of *Gpr183*^{-/-} and *Ch25h*^{-/-} Mice
 (A and B) Population frequencies (A) and numbers (B) of RORγt⁺ ILC3s in the mLNs of WT and *Gpr183*^{-/-} mice at steady state, gated on CD45⁺Lin⁻CD127⁺CD90⁺ cells. Data are representative of 3 independent experiments. **p < 0.01, ***p < 0.001.
 (C and D) Population frequencies (C) and numbers (D) of RORγt⁺ ILC3s in the mLNs of WT and *Ch25h*^{-/-} mice at steady state, gated on CD45⁺Lin⁻CD127⁺CD90⁺ cells. Data are representative of 3 independent experiments. **p < 0.01, ****p < 0.0001.
 (E-G) Representative images of mLN sections of WT and *Gpr183*^{-/-} mice stained for RORγt, CD127 and DAPI together with CD3ε (E), B220(F) or MAdCAM-1 (G). Follicles, or F, are designated by dashed lines. The scale bars represent 50 μm.
 (H) Percentages of ILC3s localized in the outer regions over ILC3s localized in the interfollicular areas between follicles in mLN sections of WT and *Gpr183*^{-/-} mice. Twenty-three interfollicular areas in 15 mLNs from 3 WT mice and 21 interfollicular areas in 15 mLNs from 3 *Gpr183*^{-/-} mice were examined. ***p < 0.001. (I and J) Representative

images of ILC3 distribution (I) and percentages of ILC3s localized in the outer regions (J) in mLN sections of WT and *Ch25h*^{-/-} mice. Ten interfollicular areas in 10 mLNs from 2 WT mice and 14 interfollicular areas in 10 mLNs from 2 *Ch25h*^{-/-} mice were examined. The scale bars represent 100 μ m. In

(J), *p < 0.05.

(K) Numbers of ILC3s in interfollicular areas (inner and outer regions) in mLN sections of WT and *Gpr183*^{-/-} mice. See Figures 2E-2H legend for details. *p < 0.05, **p < 0.01.

(L) The enumeration of anti-a4b7 geometric mean fluorescence intensity (GMFI) on mLN ILC3s of WT and *Gpr183*^{-/-} mice. Data are representative of 3 independent experiments. *p < 0.05.

Each symbol represents one mouse (A-D and L) or one region (H, J, and K). Data are mean \pm SEM. See also Figure S2.




Figure 3. Defective ILC3 Accumulation in the SI of *Gpr183*^{-/-} and *Ch25h*^{-/-} Mice

(A-D) Population frequencies (A) and numbers (B) of RORγt⁺ ILC3s and numbers of NKp46⁺RORγt⁺ ILC3s (C) and CCR6⁺RORγt⁺ ILC3s (D) in the SI of WT and *Gpr183*^{-/-} mice at steady state, gated on CD45⁺Lin⁻CD127⁺CD90⁺ cells. Data are representative of 3 independent experiments. **p < 0.01.

(E-H) Population frequencies (E) and numbers (F) of RORγt⁺ ILC3s and numbers of NKp46⁺RORγt⁺ ILC3s (G) and CCR6⁺RORγt⁺ ILC3s (H) in the SI of WT and *Ch25h*^{-/-} mice at steady state, gated on CD45⁺Lin⁻CD127⁺CD90⁺ cells. Data are pooled from 2 experiments. In (E) and (F), *p < 0.05. In (G), **p < 0.01.

(I) Representative images of ILC3 distribution and CPs in SI sections of WT and *Gpr183*^{-/-} mice. The scale bars represent 500 μm.

(J) Numbers of CPs in SI sections of WT and *Gpr183*^{-/-} mice. *p < 0.05.

(K) Ratios of CD45.2⁺ ILC3s to CD45.1⁺CD45.2⁺ ILC3s in the SI and mLNs of mixed BM chimera mice with indicated genotypes. Data are representative of 3 independent experiments. **p < 0.01, ***p < 0.001. See also Figure S3G.

(L) Frequencies of Ki67-expressing ILC3s in the SI of WT:WT (left) and *Gpr183*^{-/-}:WT (right) BM chimera mice. Data are representative of 3 independent experiments. Each symbol represents one mouse. Data are mean ± SEM. See also Figure S3.




Figure 4. GPR183 Is Required for ILC3-Mediated Protection against *C. rodentium* Infection (A-H) *Rag1*^{-/-} and *Rag1*^{-/-}*Gpr183*^{-/-} mice were infected with *C. rodentium* and were analyzed 8 (A-E and I) and 10 (F-H) days post-infection (d.p.i.). (A and B) Population frequencies (A) and numbers (B) of ILC3s in the colon LP, gated on CD45⁺Lin⁻CD127⁺CD90⁺ cells. **p < 0.01, ***p < 0.001. (C) Frequencies of Ki67-expressing colonic ILC3s. (D and E) Frequencies (D) and numbers (E) of IL-22-producing colonic ILC3s following IL-23 restimulation. In (E), *p < 0.05. (F) Representative H&E staining sections of colon (left) and enumeration of the crypt length (right). The scale bars represent 100 μm.

(G-J) Colon length (G), changes in body weight (H), *Lcn2* mRNA expression (I), and survival (J) of infected *Rag1*^{-/-} and *Rag1*^{-/-}*Gpr183*^{-/-} mice. Body weight is presented relative to initial weight, set as 100%. Survival data are pooled from 2 experiments (8 mice per group). *p < 0.05, **p < 0.01. All data are representative of 2 independent experiments unless stated. Each symbol represents one mouse. Data are mean ± SEM. See also Figure S4.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript